Irene Vourliotaki, Ingrid Elizabeth Bonapart, Catherine Stamataki, Eva-Maria Tsapakis, Catherine Saridaki
Dopamine agonists are the drugs of choice in the treatment of prolactinomas, the most common type of pituitary adenomas. However, up to 25% of prolactinomas do not respond to these drugs and alternative treatments have to be considered. We describe a 37-year old female with a microprolactinoma who, although having received all available formulations of dopamine agonists …
Mirjana Doknic, Sandra Pekic, Milorad Civcic, Vera Popovic
CONTEXT: Congenital hypopituitarism is a syndrome which is associated with single or multiple pituitary hormone deficiencies. Mutations in a number of developmental genes have been linked to combined pituitary hormone deficiencies, the most common being mutation in the pituitary …
Mussa H. Almalki, Nora Nasser Aljoaib, Maha Jurais Alotaibi, Bayan Saloum Aldabas, Tayba Saleh Wahedi, Maswood M. Ahmad, Fahad Alshahrani
Pituitary tumors represent 10-15% of all intracranial tumors; of these, prolactinomas account for 40-50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern. Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas …
Chrisanthi Zouli, Christos Tsametis, Ioannis Papadimas, Dimitrios G. Goulis
The clinical and laboratory features as well as the diagnostic and therapeutic approach of men with XYY syndrome have not been fully described. A 41-year-old infertile man was diagnosed as having a 47,XYY karyotype and a micro-prolactinoma. His 32-year-old wife had a history of five spontaneous pregnancies, all resulting in first trimester miscarriages …